(UroToday.com) Historically, it has been felt that there is a relative paucity of important germline mutations in patients with prostate cancer. However, recent work has identified important rates of mutations, particularly in DNA damage repair (DDR) pathways. The initial work in this space focused on men with advanced disease. However, more recent work has looked at this earlier in the disease process. In a podium presentation at the American Urologic Association (AUA) 2020 Virtual Annual Meeting, Randy Vince, MD, and colleagues presented an analysis examining rates of germline mutations in men with both metastatic and localized disease undergoing testing for clinical, rather than research, based indications.